system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: UNLABELLED. Meshes: ATP Binding Cassette Transporter, Subfamily B, Member 1, Animals, Antineoplastic Agents, BRCA1 Protein, Cell Line, Tumor, Chromosomal Proteins, Non-Histone, DNA Damage, DNA-Binding Proteins, Drug Resistance, Neoplasm, Enzyme Inhibitors, Female, Mammary Neoplasms, Animal, Mice, Mutation, Phthalazines, Piperazines, Piperidines, Poly(ADP-ribose) Polymerase Inhibitors, Tumor Suppressor p53-Binding Protein 1.
user
Does loss of 53BP1 cause PARP inhibitor resistance in Brca1-mutated mouse mammary tumors? Context: Inhibition of PARP is a promising therapeutic strategy for homologous recombination-deficient tumors, such as BRCA1-associated cancers. We previously reported that BRCA1-deficient mouse mammary tumors may acquire resistance to the clinical PARP inhibitor (PARPi) olaparib through activation of the P-glycoprotein drug efflux transporter. Here, we show that tumor-specific genetic inactivation of P-glycoprotein increases the long-term response of BRCA1-deficient mouse mammary tumors to olaparib, but these tumors eventually developed PARPi resistance. In a fraction of cases, this resistance is caused by partial restoration of homologous recombination due to somatic loss of 53BP1. Importantly, PARPi resistance was minimized by long-term treatment with the novel PARP inhibitor AZD2461, which is a poor P-glycoprotein substrate. Together, our data suggest that restoration of homologous recombination is an important mechanism for PARPi resistance in BRCA1-deficient mammary tumors and that the risk of relapse of BRCA1-deficient tumors can be effectively minimized by using optimized PARP inhibitors.
assistant
In this study, we show that loss of 53BP1 causes resistance to PARP inhibition in mouse mammary tumors that are deficient in BRCA1. We hypothesize that low expression or absence of 53BP1 also reduces the response of patients with BRCA1-deficient tumors to PARP inhibitors. Final Decision: yes